Avignon, FRANCE – December, 30th 2008 - During its meeting of December, 20th 2008, Naturex’s Board of Directors was informed of AFEP-MEDEF recommendations of October, 6th 2008 concerning the remuneration of directors of listed companies.
The Board considers that the company’s corporate governance practices are in line with these recommendations.
Consequently, as from the current fiscal year, and in accordance with the law of July, 3rd 2008 implementing EU directive 2006/46/CE of June, 14th 2006, the AFEP-MEDEF code hence modified is taken into account by the company when elaborating its report in accordance with article L. 225-68 of commercial law.
If you would like to receive financial information about Naturex by e-mail,
contact: www.actus-finance.com
NATUREX has been listed since October 1996 on Euronext Paris, segment C
ISIN FR0000054694, Reuters NATU.LN, Bloomberg NTRX:FP
About Naturex
|
NRX |
Naturex develops, manufactures and markets natural ingredients for the food, dietary supplement and nutraceutical, pharmaceutical, and cosmetic industries. Headquartered in Avignon, France, the group employs 550 people and has an international reach, with over 90% of its sales generated in 30 different countries outside France, 60% of which in North America. Naturex has production facilities in France, Morocco, the United States and Italy, a subsidiary in the United Kingdom, and representative offices in Germany and Singapore. www.naturex.com |
| Naturex contact: | Actus Finance contact: |
|
Jacques Dikansky, President and C.E.O. Tel.: +33 (0)4 90 23 96 89 naturex@naturex.com Thierry Lambert, Vice-President and CFO Tel.: +33 (0)4 90 23 96 89 t.lambert@naturex.com |
Laurence Marquézy, Investor Relations Tel.: +33 (0)1 72 74 82 23 lmarquezy@actus.fr Anne Catherine Bonjour, Press Relations Tel.: + 33 (0)1 53 67 36 93 acbonjour@actus.fr |